PROMISE was a study that enrolled a large, community-based population of patients with suspected coronary artery disease (CAD) and evaluated the use of two types of noninvasive testing: anatomical testing with computed tomography angiography (CTA) and functional testing. The study found that using CTA did not reduce the incidence of events, such as heart attacks or death, over a follow-up period of 25 months compared to functional testing. Both CTA and functional testing had a primary event rate of 3.1%. CTA was associated with a lower incidence of invasive catheterization showing no obstructive CAD within 90 days of the test, but this was not a primary end point of the study. Overall, the study found that both CTA and functional testing were safe and effective for the evaluation of CAD symptoms.
https://www.nejm.org/doi/full/10.1056/nejmoa1415516
Leave a Reply